Late Breaking Abstract - Anti-IL-5 therapy is associated with sustained improvement in FEV1 in severe eosinophilic asthma patients. - Milan 2023

Unravelling the potential of interleukin-5 pathways in asthma

Chair(s): Asger Sverrild, Zuzana Diamant

Session type: Poster session

Late Breaking Abstract - Anti-IL-5 therapy is associated with sustained improvement in FEV1 in severe eosinophilic asthma patients.

Nathan Blekic

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Mepolizumab for the treatment of Eosinophilic Granulomatosis Polyangitis(EGPA) at Jersey General Hospital: A case review series; clinical features, diagnostic tests and management.

Kesavaperumal Vijayasaratha

Poster

Abstract

Asthma outcomes in patients (pts) with severe eosinophilic asthma (SEA), with and without comorbid chronic rhinosinusitis with nasal polyps (NP), treated with benralizumab in the real-world XALOC-1 study

Alicia Padilla Galo

Poster

Abstract

Late Breaking Abstract - Anti-IL-5 therapy is associated with sustained improvement in FEV1 in severe eosinophilic asthma patients.

Nathan Blekic

Poster

Abstract

Implementation of the FEOS score in patients with severe eosinophilic asthma treated with Reslizumab.

Katiuska Herminia Liendo Martinez

Poster

Abstract

Real-world benralizumab effectiveness in patients with severe eosinophilic asthma on a 3 year follow up.

Giulia Lo Muzio

Poster

Abstract

Efficacy of Mepolizumab in a cohort of patients with severe eosinophilic asthma after 5 years of treatment: a single centre study

Gerardo Nazzaro

Poster

Abstract

Real-world effectiveness and characteristics of Super-Responders to Mepolizumab and Benralizumab in severe eosinophilic asthma and EGPA

Andrea Portacci

Poster

Abstract

The experience of reslizumab treatment for frequent relapsing chronic eosinophilic pneumonia accompanying asthma: a case series

Seung-eun Lee

Poster

Abstract

Long-term effectiveness of Mepolizumab in patients with refractory severe eosinophilic asthma.

Victor Garcia Garcia

Poster

Abstract

Mepolizumab and Benralizumab: new therapeutic perspectives for Severe Eosinophilic Asthma and Eosinophilic Granulomatosis with Polyangiitis

Paola Scarano

Poster

Abstract

Mepolizumab improves small airway disease in severe eosinophilic asthmatics

Francesca Cefaloni

Poster

Abstract

Evaluation of the effects of Benralizumab on Nasal Inflammation in Severe Eosinophilic Refractory Asthma and Nasal Polyposis

Claudio Candia

Poster

Abstract

Benralizumab effectiveness in patients with severe asthma regardless of prior biologic use: A real-world Canadian experience

Sheena Kayaniyil

Poster

Abstract

Retrospective study to assess response to benralizumab in elderly asthma patients

Eve Coleborn

Poster

Abstract

Impact of age on the efficacy of mepolizumab in severe uncontrolled asthma

Francisco-javier Gonzalez Barcala

Poster

Abstract

Outcomes of blocking IL-5 in severe asthma elderly patients

David Banas Conejero

Poster

Abstract

Switching things up: experience of second line anti-interleukin-5 therapy for severe asthma

Fred Fyles

Poster

Abstract

Disease remission in severe asthma patients on mepolizumab treatment and its duration after treatment discontinuation.

Piotr Damianski

Poster

Abstract

A retrospective cohort study to determine if Interluekin 5 inhibitors reduce oral corticosteroid burden in Severe Asthma in real life

Zoe Chan

Poster

Abstract

Late Breaking Abstract - Durability of response after 96 weeks of treatment with benralizumab: results from the Italian ANANKE study

Silvia Boarino

Poster

Abstract

CDN Connection Issue

The ERS International Congress 2023, Milan

#{title}